

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM C**

**UNDER THE SECURITIES ACT OF 1933**

(Mark one.)

- ☐ Form C: Offering Statement
- ☐ Form C-U: Progress Update
- ☐ Form C/A: Amendment to Offering Statement
  - ☐ Check box if Amendment is material and investors must reconfirm within five business days.
- ☒ Form C-AR: Annual Report
- ☐ Form C-AR/A: Amendment to Annual Report
- ☐ Form C-TR: Termination of Reporting

***Name of issuer***

Pistil & Pollen, LLC dba Jane West

***Legal status of issuer***

***Form***

Limited Liability Company

***Jurisdiction of Incorporation/Organization***

Delaware

***Date of organization***

March 16, 2016

***Physical address of issuer***

5082 East Hampden Avenue, Suite 242, Denver, CO 80222

***Website of issuer***

www.janewest.com

***Current number of employees***

2<sup>1</sup>

---

<sup>1</sup> Both employees are employed by Electric Feel, LLC, a wholly-owned subsidiary of Pistil & Pollen, LLC.

|                                    | Most recent fiscal year-end | Prior fiscal year-end* |
|------------------------------------|-----------------------------|------------------------|
| <b>Total Assets</b>                | \$474,391                   | \$244,588              |
| <b>Cash &amp; Cash Equivalents</b> | \$95,697                    | \$19,481               |
| <b>Accounts Receivable</b>         | \$25,452                    | \$12,900               |
| <b>Short-term Debt</b>             | \$681,171                   | \$444,148              |
| <b>Long-term Debt</b>              | \$ 0                        | \$ 0                   |
| <b>Revenues/Sales</b>              | \$369,193                   | \$202,814              |
| <b>Cost of Goods Sold</b>          | \$191,004                   | \$107,275              |
| <b>Taxes Paid</b>                  | \$0.00                      | \$0.00                 |
| <b>Net Income</b>                  | (\$296,466)                 | (\$374,839)            |

\* **Revised from prior filing.**

***The jurisdictions in which the issuer intends to offer the Securities:***

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District Of Columbia, Florida, Georgia, Guam, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virgin Islands, U.S., Virginia, Washington, West Virginia, Wisconsin, Wyoming, American Samoa, and Northern Mariana Islands

**April 30, 2021**

**FORM C-AR**

**Pistil & Pollen, LLC**



This Form C-AR (including the cover page and all exhibits attached hereto, the “**Form C- AR**”) is being furnished by Pistil & Pollen, LLC, a Delaware limited liability company (the “**Company**,” as well as references to “**we**,” “**us**,” or “**our**”) for the sole purpose of providing certain information about the Company as required by the Securities and Exchange Commission (“**SEC**”).

**No federal or state securities commission or regulatory authority has passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the accuracy or completeness of any disclosure document or literature. The Company is filing this Form C-AR pursuant to Regulation Crowdfunding (§ 227.100 et seq.) (“Regulation CF”) which requires that it must file a report with the SEC annually and post the report on its website at [www.janewest.com](http://www.janewest.com) no later than 120 days after the end of each fiscal year covered by the report. The Company may terminate its reporting obligations in the future in accordance with Rule 202(b) of Regulation CF (§ 227.202(b)) by (1) being required to file reports under Section 13(a) or Section 15(d) of the Exchange Act of 1934, as amended, (2) filing at least one annual report pursuant to Regulation CF and having fewer than 300 holders of record, (3) filing annual reports for three years pursuant to Regulation CF and having assets equal to or less than \$10,000,000, (4) the repurchase of all the Securities sold pursuant to Regulation CF by the Company or another party, or (5) the liquidation or dissolution of the Company.**

The date of this Form C-AR is April 30, 2021.

THIS FORM C-AR DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR SELL SECURITIES.

### ***Forward Looking Statement Disclosure***

*This Form C-AR and any documents incorporated by reference herein or therein contain forward-looking statements and are subject to risks and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included in this Form C-AR forward looking statements. Forward Looking statements give the Company's current reasonable expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. You can identify forward looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "should," "can have," "likely" and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.*

*The forward looking statements contained in this Form C-AR and any documents incorporated by reference herein or therein are based on reasonable assumptions the Company has made in light of its industry experience, perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. As you read and consider this Form C-AR, you should understand that these statements are not guarantees of performance or results. They involve risks, uncertainties (many of which are beyond the Company's control) and assumptions. Although the Company believes that these forward looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual operating and financial performance and cause its performance to differ materially from the performance anticipated in the forward looking statements. Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove incorrect or change, the Company's actual operating and financial performance may vary in material respects from the performance projected in these forward- looking statements.*

*Any forward looking statement made by the Company in this Form C-AR or any documents incorporated by reference herein or therein speaks only as of the date of this Form C-AR. Factors or events that could cause our actual operating and financial performance to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company undertakes no obligation to update any forward looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.*

## **Table of Contents**

|   |    |
|---|----|
| SUMMARY   | 6  |
| The Business  | 6  |
| RISK FACTORS  | 6  |
| Risks Related to the Company’s Business and Industry        | 6  |
| BUSINESS  | 17 |
| Description of the Business                                 | 17 |
| Business Plan   | 17 |
| History of the Business                                     | 17 |
| The Company’s Products and/or Services                      | 19 |
| Competition   | 20 |
| Supply Chain and Customer Base                              | 20 |
| Intellectual Property                                       | 21 |
| Governmental/Regulatory Approval and Compliance             | 23 |
| Litigation  | 23 |
| Other   | 23 |
| DIRECTORS, OFFICERS AND EMPLOYEES                           | 24 |
| Managers  | 24 |
| Officers  | 25 |
| Employees   | 25 |
| CAPITALIZATION AND OWNERSHIP                                | 26 |
| Capitalization  | 26 |
| Ownership   | 28 |
| FINANCIAL INFORMATION                                       | 29 |
| Operations  | 29 |
| Liquidity and Capital Resources                             | 29 |
| Capital Expenditures and Other Obligations                  | 29 |
| Trends and Uncertainties                                    | 29 |
| TRANSACTIONS WITH RELATED PERSONS AND CONFLICTS OF INTEREST | 31 |
| Related Person Transactions                                 | 31 |
| Conflicts of Interest                                       | 31 |
| OTHER INFORMATION   | 31 |
| Bad Actor Disclosure  | 33 |
| EXHIBITS  | 33 |
| EXHIBIT A   |    |

## About this Form C-AR

You should rely only on the information contained in this Form C-AR. We have not authorized anyone to provide you with information different from that contained in this Form C-AR. You should assume that the information contained in this Form C-AR is accurate only as of the date of this Form C-AR, regardless of the time of delivery of this Form C-AR. Our business, financial condition, results of operations, and prospects may have changed since that date.

Statements contained herein as to the content of any agreements or other documents are summaries and, therefore, are necessarily selective and incomplete and are qualified in their entirety by the actual agreements or other documents.

## SUMMARY

The following summary is qualified in its entirety by the more detailed information that may appear elsewhere in this Form C-AR.

Pistil & Pollen, LLC (the “**Company**”) is a Delaware limited liability company formed on March 16, 2016. Pistil & Pollen, LLC was formed to assume and develop the business of Jane West, LLC, formed January 5, 2014 by Amy Dannemiller, related to brand and product development around the “Jane West” name and marks.

The Company is located at 5082 East Hampden Avenue, Suite 242, Denver, CO 80222.

The Company’s website is [www.janewest.com](http://www.janewest.com).

The information available on or through our website is not a part of this Form C-AR.

## The Business

We curate, design and sell a variety of products for cannabis consumers. We earn revenue through licensing, packaging and product sales.

## RISK FACTORS

*The SEC requires the Company to identify risks that are specific to its business and financial condition. The Company is still subject to all the same risks that all companies in its business, and all companies in the economy, are exposed to. These include risks relating to economic downturns, political and economic events and technological developments (such as hacking and the ability to prevent hacking). Additionally, early-stage companies are inherently riskier than more developed companies. You should consider general risks as well as specific risks when deciding whether to invest.*

### Risks Related to the Company’s Business and Industry

*In order for the Company to compete and grow, it must attract, recruit, retain and develop the necessary personnel who have the needed experience.*

Recruiting and retaining highly qualified personnel is critical to our success. These demands may require us to hire additional personnel and will require our existing management personnel to develop additional expertise. We face intense competition for personnel. The failure to attract and retain personnel or to develop such expertise could delay or halt the development and commercialization of our product

candidates. If we experience difficulties in hiring and retaining personnel in key positions, we could suffer from delays in product development, loss of customers and sales and diversion of management resources, which could adversely affect operating results. Our consultants and advisors may be employed by third parties and may have commitments under consulting or advisory contracts with third parties that may limit their availability to us.

***In order for the company to continue as a going concern, it must raise member capital to fund its operations.***

Since inception, the Company has relied on member capital to fund its operations. As of December 31, 2020, the Company has not reached profitability and will likely incur additional losses prior to generating positive cash flow from operations.

***The development and commercialization of our products is fragmented with a variety of existing and emerging competitors.***

We are producing products to facilitate the combustion and use of medical and recreational cannabis as well as for dry herb combustion and consumption. Competition for these products comes from manufacturers producing glass accessories used for these purposes as well as manufacturers of smokers' accessories that may be repurposed by cannabis consumers. We do not currently face competition from a major cannabis accessory company that also leverages the brand for licensing revenue as the market in the United States is relatively new and developing. Our competitors for the glassware currently include artisans producing smokers' accessories for sale and distribution into local smoke shops and medical and recreational dispensaries in legal cannabis markets. Additionally, dispensaries may offer accessories they source from a multitude of manufacturers offering products on such sources as Alibaba. Our existing competitors, or new entrants to the market, may commercialize products more rapidly or effectively than we are able to, which would adversely affect our competitive position and the likelihood that our products will achieve market acceptance as well as our ability to generate meaningful additional revenues from our products.

***We rely on other companies to provide materials for our products.***

We depend on these suppliers through our manufacturers. Our proprietary product line, which we refer to as the "Collection" was designed and refined with commercial manufacturing facilities that source all of the underlying inputs. Our ability to manufacture may be adversely affected if suppliers or subcontractors of our factories do not provide the agreed upon supplies or perform the agreed upon services in a timely and cost effective manner. Likewise, the quality of our products may be adversely impacted if companies to whom we delegate manufacture of major components or subsystems for our products, or from whom we acquire such items, do not provide materials which meet required specifications and perform to our and our customers' expectations. Our suppliers may be less likely than us to be able to quickly recover from natural disasters and other events beyond their control and may be subject to additional risks such as financial problems that limit their ability to conduct their operations. The risk of these adverse effects may be greater in circumstances where we rely on only one or two subcontractors or suppliers for particular materials.

***We depend on third party service providers and outsource providers for a variety of services and we outsource a number of our non-core functions and operations.***

In certain instances, we rely on single or limited service providers and outsourcing vendors around the world because the relationship is advantageous due to quality, price, or lack of alternative sources. If production or service was interrupted and we were not able to find alternate third party providers, we could experience disruptions in manufacturing and operations including product shortages, higher freight costs and re-engineering costs. If outsourcing services are interrupted or not performed or the performance is poor, this could impact our ability to process, record and report transactions with our customers and other constituents. Such interruptions in the provision of supplies and/or services could result in our inability to meet customer demand, damage our reputation and customer relationships and adversely affect our

business.

***We depend on third party providers, suppliers and licensors to supply some of the hardware, software and operational support necessary to provide some of our services.***

We obtain these materials from a limited number of vendors, some of which do not have a long operating history or which may not be able to continue to supply the equipment and services we desire. Some of our hardware, software and operational support vendors represent our sole source of supply or have, either through contract or as a result of intellectual property rights, a position of some exclusivity. If demand exceeds these vendors' capacity or if these vendors experience operating or financial difficulties, or are otherwise unable to provide the equipment or services we need in a timely manner, at our specifications and at reasonable prices, our ability to provide some services might be materially adversely affected, or the need to procure or develop alternative sources of the affected materials or services might delay our ability to serve our customers. These events could materially and adversely affect our ability to retain and attract customers, and have a material negative impact on our operations, business, financial results and financial condition.

***Quality management plays an essential role in determining and meeting customer requirements, preventing defects, improving the Company's products and services and maintaining the integrity of the data that supports the safety and efficacy of our products.***

Our future success depends on our ability to maintain and continuously improve our quality management program. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products. In addition, a successful claim brought against us in excess of available insurance or not covered by indemnification agreements, or any claim that results in significant adverse publicity against us, could have an adverse effect on our business and our reputation.

***Manufacturing or design defects, unanticipated use of our products, or inadequate disclosure of risks relating to the use of the products can lead to injury or other adverse events.***

These events could lead to recalls or safety alerts relating to our products (either voluntary or required by governmental authorities) and could result, in certain cases, in the removal of a product from the market. Any recall could result in significant costs as well as negative publicity that could reduce demand for our products. Personal injuries relating to the use of our products can also result in product liability claims being brought against us. In some circumstances, such adverse events could also cause delays in new product approvals. Similarly, negligence in performing our services can lead to injury or other adverse events.

***We plan to implement new lines of business or offer new products and services within existing lines of business.***

There are substantial risks and uncertainties associated with these efforts, particularly in instances where the markets are not fully developed. In developing and marketing new lines of business and/or new products and services, we may invest significant time and resources. Initial timetables for the introduction and development of new lines of business and/or new products or services may not be achieved and price and profitability targets may not prove feasible. We may not be successful in introducing new products and services in response to industry trends or developments in technology, or those new products may not achieve market acceptance. As a result, we could lose business, be forced to price products and services on less advantageous terms to retain or attract clients, or be subject to cost increases. As a result, our business, financial condition or results of operations may be adversely affected.

***In general, demand for our products and services is highly correlated with general economic conditions.***

A substantial portion of our revenue is derived from discretionary spending by individuals, which typically falls during times of economic instability. Declines in economic conditions in the U.S. or in other countries



in which we operate may adversely impact our consolidated financial results. Because such declines in demand are difficult to predict, we or the industry may have increased excess capacity as a result. An increase in excess capacity may result in declines in prices for our products and services.

***Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.***

Through third party service providers we indirectly collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, and personally identifiable information of our customers and employees. The secure processing, maintenance and transmission of this information is critical to our operations and business strategy. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise the information stored there and result in unauthorized access, public disclosure or, lost or stolen information. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and potential regulatory penalties, disrupt our operations and the services we provide to customers, and damage our reputation, and cause a loss of confidence in our products and services, which could adversely affect our business/operating margins, revenues and competitive position.

***An intentional or unintentional disruption, failure, misappropriation or corruption of our network and information systems could severely affect our business.***

Such an event might be caused by computer hacking, computer viruses, worms and other destructive or disruptive software, "cyber attacks" and other malicious activity, as well as natural disasters, power outages, terrorist attacks and similar events. Such events could have an adverse impact on us and our customers, including degradation of service, service disruption, excessive call volume to call centers and damage to our plant, equipment and data. In addition, our future results could be adversely affected due to the theft, destruction, loss, misappropriation or release of confidential customer data or intellectual property. Operational or business delays may result from the disruption of network or information systems and the subsequent remediation activities. Moreover, these events may create negative publicity resulting in reputation or brand damage with customers.

***We are required to comply with various import laws and export control and economic sanctions laws, which may affect our transactions with certain customers, business partners and other persons and dealings between our employees and subsidiaries.***

In certain circumstances, export control and economic sanctions regulations may prohibit the export of certain products, services and technologies. In other circumstances, we may be required to obtain an export license before exporting the controlled item. Compliance with the various import laws that apply to our businesses can restrict our access to, and increase the cost of obtaining, certain products and at times can interrupt our supply of imported inventory.

***The Company's success depends on the experience and skill of the board of managers, its executive officers and key employees.***

In particular, the Company is dependent on Amy Dannemiller who is the Chief Executive Officer of the Company. The Company intends to enter into an employment agreement with Amy Dannemiller although there can be no assurance that it will do so or that she will continue to be employed by the Company for a particular period of time. The loss of Amy Dannemiller or any manager or executive officer could harm the Company's business, financial condition, cash flow and results of operations.

***We rely on third-party suppliers for the materials used in the manufacturing of our products.***

In 2019, the following suppliers provided the following percentage of the listed services, inputs or raw materials:

Supplier or Description: Greenlane Pollen Gear  
Service: ASTM, CPSC Child-Resistant Packaging  
% of such service: 100.0%

Supplier or Description: Can-Tek Lab's, LLC  
Service: DAY & NIGHT Capsules  
% of such service: 100.0%

Supplier or Description: Steepfuze, LLC  
Service: LIGHT & DARK Coffee  
% of such service: 100.0%

Supplier: Life-N-Living  
Service: Travel Collection manufacturing  
% of such services 100%

Supplier: Kush Supply Co.  
Service: Custom joint tips  
% of such services 100%

Supplier: WHT LBL  
Service: Handrolled Hemp mini joints  
% of such services 100%

Supplier: PRE-PACKS, LLC  
Service: Packaging, Glass Container Manufacturing  
% of such services 100%

Supplier: Elmore Mountain Therapeutics  
Service: Topicals, Travel Stick 100 mg CBD % of such services 100%

Supplier: Famous Brandz  
Service: Homegoods, Accessories, Glassware  
% of such services 100%

If any of these suppliers changed its sales strategy to reduce its reliance on distribution channels, or decided to terminate its business relationship with us, sales and earnings could be adversely affected until we are able to establish relationships with suppliers of comparable products. Any delay or interruption in manufacturing operations (or failure to locate a suitable replacement for such suppliers) could materially adversely affect our business, prospects, or results of operations. Most of our agreements with suppliers are terminable by either party on short notice for any reason. Although we believe our relationships with these key suppliers are good, they could change their strategies as a result of a change in control, expansion of their direct sales force, changes in the marketplace or other factors beyond our control, including a key supplier becoming financially distressed.

***We rely on various intellectual property rights, including trademarks in order to operate our business.***

Such intellectual property rights, however, may not be sufficiently broad or otherwise may not provide us a significant competitive advantage. In addition, the steps that we have taken to maintain and protect our intellectual property may not prevent it from being challenged, invalidated, circumvented or designed

-around, particularly in countries where intellectual property rights are not highly developed or protected. In some circumstances, enforcement may not be available to us because an infringer has a dominant intellectual property position or for other business reasons, or countries may require compulsory licensing of our intellectual property. Our failure to obtain or maintain intellectual property rights that convey competitive advantage, adequately protect our intellectual property or detect or prevent circumvention or unauthorized use of such property, could adversely impact our competitive position and results of operations. We also rely on nondisclosure and noncompetition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary rights. There can be no assurance that these agreements will adequately protect our trade secrets and other proprietary rights and will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or other proprietary rights.

As we expand our business, protecting our intellectual property will become increasingly important. The protective steps we have taken may be inadequate to deter our competitors from using our proprietary information. In order to protect or enforce our patent rights, we may be required to initiate litigation against third parties, such as infringement lawsuits. Also, these third parties may assert claims against us with or without provocation. These lawsuits could be expensive, take significant time and could divert management's attention from other business concerns. The law relating to the scope and validity of claims in the technology field in which we operate is still evolving and, consequently, intellectual property positions in our industry are generally uncertain. We cannot assure you that we will prevail in any of these potential suits or that the damages or other remedies awarded, if any, would be commercially valuable.

***From time to time, third parties may claim that one or more of our products or services infringe their intellectual property rights.***

Any dispute or litigation regarding patents or other intellectual property could be costly and time consuming due to the complexity of our technology and the uncertainty of intellectual property litigation and could divert our management and key personnel from our business operations. A claim of intellectual property infringement could force us to enter into a costly or restrictive license agreement, which might not be available under acceptable terms or at all, could require us to redesign our products, which would be costly and time consuming, and/or could subject us to an injunction against development and sale of certain of our products or services. We may have to pay substantial damages, including damages for past infringement if it is ultimately determined that our product candidates infringe a third party's proprietary rights. Even if these claims are without merit, defending a lawsuit takes significant time, may be expensive and may divert management's attention from other business concerns. Any public announcements related to litigation or interference proceedings initiated or threatened against us could cause our business to be harmed. Our intellectual property portfolio may not be useful in asserting a counterclaim, or negotiating a license, in response to a claim of intellectual property infringement. In certain of our businesses we rely on third party intellectual property licenses and we cannot ensure that these licenses will be available to us in the future on favorable terms or at all.

***We have not prepared any audited financial statements.***

Therefore, you have no audited financial information regarding the Company's capitalization or assets or liabilities on which to make your investment decision. If you feel the information provided is insufficient, you should not invest in the Company.

***We are subject to income taxes as well as non-income based taxes, such as payroll, sales, use, value-added, net worth, property and goods and services taxes.***

Significant judgment is required in determining our provision for income taxes and other tax liabilities. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination is uncertain. Although we believe that our tax estimates are reasonable: (i) there is no

assurance that the final determination of tax audits or tax disputes will not be different from what is reflected in our income tax provisions, expense amounts for non-income based taxes and accruals and (ii) any material differences could have an adverse effect on our financial position and results of operations in the period or periods for which determination is made.

***We are not subject to Sarbanes-Oxley regulations and lack the financial controls and safeguards required of public companies.***

We do not have the internal infrastructure necessary, and are not required, to complete an attestation about our financial controls that would be required under Section 404 of the Sarbanes- Oxley Act of 2002. There can be no assurance that there are no significant deficiencies or material weaknesses in the quality of our financial controls. We expect to incur additional expenses and diversion of management's time if and when it becomes necessary to perform the system and process evaluation, testing and remediation required in order to comply with the management certification and auditor attestation requirements.

***The Company has indicated that it has engaged in certain transactions with related persons.***

Please see the section of this Memorandum entitled "Transactions with Related Persons and Conflicts of Interest" for further details.

***Changes in employment laws or regulation could harm our performance.***

Various federal and state labor laws govern our relationship with our employees and affect operating costs. These laws include minimum wage requirements, overtime pay, healthcare reform and the implementation of the Patient Protection and Affordable Care Act, unemployment tax rates, workers' compensation rates, citizenship requirements, union membership and sales taxes. A number of factors could adversely affect our operating results, including additional government- imposed increases in minimum wages, overtime pay, paid leaves of absence and mandated health benefits, mandated training for employees, increased tax reporting and tax payment requirements for employees who receive tips, a reduction in the number of states that allow tips to be credited toward minimum wage requirements, changing regulations from the National Labor Relations Board and increased employee litigation including claims relating to the Fair Labor Standards Act.

***Medical-use and/ or recreational-use of cannabis remains illegal under federal law, and therefore, strict enforcement of federal laws regarding medical--use or recreational-use of cannabis would prevent us from executing our business plan.***

Cannabis is a Schedule I controlled substance under the Controlled Substance Act ("CSA"). Even in those jurisdictions in which the manufacture and use of medical and/ or recreational cannabis has been legalized at the state level, the possession, use and cultivation all remain violations of federal law that are punishable by imprisonment and substantial fines. Moreover, individuals and entities may violate federal law if they intentionally aid and abet another in violating these federal controlled substance laws, or conspire with another to violate them. The U.S. Supreme Court has ruled in *United States v. Oakland Cannabis Buyers' Coop.* and *Gonzales v. Raich* that it is the federal government that has the right to regulate and criminalize cannabis, even for medical purposes. We may be unable to execute our business plan if the federal government were to strictly enforce federal law regarding cannabis. We would have to reposition the marketing and use of our products for dry herbs and would have to discontinue packaging sales related to branded cannabis.

The Rohrbacher-Blumenauer amendment, which protects medical cannabis patients and caregivers in legal medical states by prohibiting the U.S. Department of Justice (which includes the DEA) from using federal funds to prevent states from implementing their medical- use cannabis laws. is in effect until February 8, 2018. Congress will then need to include provisions for extension in the budget, pass new legislation or these federal protections may expire. In *USA vs. McIntosh*, the United States Court of Appeals for the Ninth Circuit held that this provision prohibits the U.S. Department of Justice from spending funds from

relevant appropriations acts to prosecute individuals who engage in conduct permitted by state medical- use cannabis laws and who strictly comply with such laws. However, the Ninth Circuit’s opinion, which only applies to the states of Alaska, Arizona, California, Hawaii, and Idaho, also held that persons who do not strictly comply with all state laws and regulations regarding the distribution, possession and cultivation of medical use cannabis have engaged in conduct that is unauthorized, and in such instances the U.S. Department of Justice may prosecute those individuals.

Additionally, financial transactions involving proceeds generated by cannabis related conduct can form the basis for prosecution under the federal money laundering statutes, unlicensed money transmitter statutes and the Bank Secrecy Act. The Company does not sell cannabis however it may receive proceeds from licensed cannabis processors or producers.

Based on the Trump administration in general and the stated position of the Attorney General of the United States in particular, there is also no guarantee that the current administration or future administrations will not revise federal enforcement priorities and choose to strictly enforce the federal laws governing cannabis production or distribution. At this time, it is unknown whether the Trump administration will change the federal government’s current enforcement posture with respect to state licensed medical use cannabis. Any such change in the federal government’s current enforcement posture with respect to state licensed cultivation of medical use cannabis would result in our inability to execute our business plan and we would suffer significant losses and may be required to cease operations.

Any changes in state or local laws that reduce or eliminate the ability of companies that acquire our products or packaging to cultivate and produce medical use cannabis would materially and negatively impact on our business.

***Our ability to grow our business depends on state laws pertaining to the cannabis industry.***

Continued development of the medical use cannabis industry depends upon continued legislative authorization of cannabis at the state level. The status quo of, or progress in, the regulated medical use cannabis industry is not assured and any number of factors could slow or halt further progress in this area. While there may be ample public support for legislative action permitting the manufacture and use of cannabis, numerous factors impact the legislative process. In addition, burdensome regulation at the state level could slow or stop further development of the medical use cannabis industry, such as limiting the medical conditions for which medical cannabis can be recommended by physicians for treatment, restricting the form in which medical cannabis can be consumed, imposing significant registration requirements on physicians and patients or imposing significant taxes on the growth, processing and/or retail sales of cannabis, which could have the impact of dampening growth of the cannabis industry and making it difficult for cannabis businesses to operate profitably in those states.

FDA regulation of medical use cannabis and the possible registration of facilities where medical- use cannabis is grown could negatively affect the medical use cannabis industry and our financial condition.

Should the federal government legalize cannabis for medical use, it is possible that the U.S. Food and Drug Administration (“FDA”) would seek to regulate it under the Food, Drug and Cosmetics Act of 1938. Additionally, the FDA may issue rules and regulations including certified good manufacturing practices, or cGMPs, related to the growth, cultivation, harvesting and processing of medical cannabis. Clinical trials may be needed to verify efficacy and safety. It is also possible that the FDA would require that facilities where medical use cannabis is grown register with the FDA and comply with certain federally prescribed regulations. In the event that some or all of these regulations are imposed, we do not know what the impact would be on the medical use cannabis industry, including what costs, requirements and possible prohibitions may be enforced. If we are or consumers of our packaging and products are unable to comply with the regulations or registration as prescribed by the FDA, we may be unable to continue to operate.

***We may have difficulty accessing the service of banks, which may make it difficult to operate our business and conduct certain business transactions.***

Financial transactions involving proceeds generated by cannabis related conduct can form the basis for prosecution under the federal money laundering statutes, unlicensed money transmitter statute and the Bank Secrecy Act. Financial institutions may err on the side of caution when choosing to bank companies due to a perceived risk of such companies being “cannabis” companies (even if we don’t touch the plant). Recent guidance issued by the Financial Crimes Enforcement Network, a division of the U.S. Department of the Treasury, clarifies how financial institutions can provide services to cannabis- related businesses consistent with their obligations under the Bank Secrecy Act. Nevertheless, businesses involved in (or perceived to be involved in) the regulated medical use cannabis industry continue to encounter difficulty establishing and/ or maintaining banking relationships. The inability of our licensed counterparts to maintain bank accounts, or closure of our bank accounts, would make it difficult for us to operate our business, increase our operating costs, and pose additional operational, logistical and security challenges and could result in our inability to implement our business plan.

***The SEC is monitoring the cannabis industry and may halt or prevent the Offering or sale of our securities due to the bad acts of others.***

On May 16, 2014, the SEC’s Office of Investor Education and Advocacy issued an Investor Alert to warn investors about potential risks involving investments in cannabis related companies. The SEC noted an increase in the number of investor complaints regarding cannabis related investments. The SEC issued temporary trading suspensions for the common stock of five different cannabis related companies. Due to the stigma created by the bad acts of others in the industry, the SEC may halt trading and offerings in all cannabis related companies which would have a material adverse effect on our ability to raise capital and our business.

***Laws and regulations affecting the regulated cannabis industry and state specific definitions of paraphernalia are constantly changing, which could materially adversely affect our proposed operations, and we cannot predict the impact that future regulations may have on us.***

Local, state and federal cannabis laws and regulations are broad in scope and subject to evolving interpretations, which could require us to incur substantial costs associated with compliance or alter our business plan. In addition, violations of these laws, or allegations of such violations, could disrupt our business and result in a material adverse effect on our operations. It is also possible that regulations may be enacted in the future that will be directly applicable to our proposed business. We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business.

***Applicable state laws may prevent us from maximizing our potential income.***

Depending on the laws of each particular state, we may not be able to fully realize our potential to generate profit. Furthermore, cities and counties are being given broad discretion to ban certain cannabis activities. Even if these activities are legal under state law, specific cities and counties may ban them.

***Maintaining, extending and expanding our reputation and brand image are essential to our business success.***

We seek to maintain, extend, and expand our brand image through marketing investments, including advertising and consumer promotions, and product innovation. Increasing attention on marketing could adversely affect our brand image. It could also lead to stricter regulations and greater scrutiny of marketing practices or more generally of our business. Existing or increased legal or regulatory restrictions on our advertising, consumer promotions and marketing, or our response to those restrictions, could limit our efforts to maintain, extend and expand our brands. Moreover, adverse publicity about regulatory or legal

action against us could damage our reputation and brand image, undermine our customers' confidence and reduce long-term demand for our products, even if the regulatory or legal action is unfounded or not material to our operations.

In addition, our success in maintaining, extending, and expanding our brand image depends on our ability to adapt to a rapidly changing media environment. We increasingly rely on social media and online dissemination of advertising campaigns. The growing use of social and digital media increases the speed and extent that information or misinformation and opinions can be shared. Facebook and Instagram have shut down accounts of cannabis businesses and some cannabis related posts are blocked by the social media platforms. Having our social media accounts shut down or blocked could seriously damage our brand or reputation. Negative posts or comments about us, our brands or our products on social or digital media, whether or not valid, could seriously damage our brands and reputation. If we do not establish, maintain, extend and expand our brand image, then our product sales, financial condition and results of operations could be adversely affected.

***Product safety and quality concerns, including concerns related to perceived quality of ingredients, could negatively affect the Company's business.***

The Company's success depends in large part on its ability to maintain consumer confidence in the safety and quality of all its products. The Company has rigorous product safety and quality standards. However, if products taken to market are or become contaminated or adulterated, the Company may be required to conduct costly product recalls and may become subject to product liability claims and negative publicity, which would cause its business to suffer. In addition, regulatory actions, activities by nongovernmental organizations and public debate and concerns about perceived negative safety and quality consequences of certain materials in our products may erode consumers' confidence in the safety and quality issues, whether or not justified, and could result in additional governmental regulations concerning the marketing and labeling of the Company's products, negative publicity, or actual or threatened legal actions, all of which could damage the reputation of the Company's products and may reduce demand for the Company's products.

***We must correctly predict, identify, and interpret changes in consumer preferences and demand, offer new products to meet those changes, and respond to competitive innovation.***

Consumer preferences may result in the need for our products to change continually. Our success depends on our ability to predict, identify, and interpret the tastes and habits of consumers and to offer products that appeal to consumer preferences. If we do not offer products that appeal to consumers, our sales and market share will decrease. We must distinguish between short term fads, mid-term trends, and long term changes in consumer preferences. If we do not accurately predict which shifts in consumer preferences will be long term, or if we fail to introduce new and improved products to satisfy those preferences, our sales could decline. If we fail to expand our product offerings successfully across product categories, or if we do not rapidly develop products in faster growing and more profitable categories, demand for our products could decrease, which could materially and adversely affect our product sales, financial condition, and results of operations.

In addition, achieving growth depends on our successful development, introduction, and marketing of innovative new products and line extensions. Successful innovation depends on our ability to correctly anticipate customer and consumer acceptance, to obtain, protect and maintain necessary intellectual property rights, and to avoid infringing the intellectual property rights of others and failure to do so could compromise our competitive position and adversely impact our business.

***We are vulnerable to fluctuations in the price and supply of ingredients, packaging materials, and freight.***

The prices of the material, packaging materials and freight are subject to fluctuations in price attributable

to, among other things, changes in supply and demand. Freight charges in particular vary widely when air is used rather than container shipment. We may choose to ship goods in small batches by air to ensure smooth delivery and operations. The sales prices to our customers are a delivered price. Therefore, changes in our input and specifically shipping costs could impact our gross margins. Our ability to pass along higher costs through price increases to our customers is dependent upon competitive conditions and pricing methodologies employed in the various markets in which we compete. To the extent competitors do not also increase their prices, customers and consumers may choose to purchase competing products or may shift purchases to lower-priced or other value offerings which may adversely affect our results of operations.

The supply and price are subject to market conditions and are influenced by other factors beyond our control. We do not have long term contracts with many of our suppliers, and, as a result, they could increase prices or fail to deliver. The occurrence of any of the foregoing could increase our costs and disrupt our operations.

***Substantial disruption to production at our manufacturing and distribution facilities could occur.***

A disruption in production at our third party manufacturing facilities could have an adverse effect on our business. In addition, a disruption could occur at the facilities of our suppliers or distributors. The disruption could occur for many reasons, including fire, natural disasters, weather, water scarcity, manufacturing problems, disease, strikes, transportation or supply interruption, government regulation, cybersecurity attacks or terrorism. Alternative facilities with sufficient capacity or capabilities may not be available, may cost substantially more or may take a significant time to start production, each of which could negatively affect our business and results of operations.

***Future product recalls or safety concerns could adversely impact our results of operations.***

We may be required to recall certain of our products should they be mislabeled, tampered with or damaged. We also may become involved in lawsuits and legal proceedings if it is alleged that the use of any of our products causes injury, illness or death. A product recall or an adverse result in any such litigation could have an adverse effect on our business, depending on the costs of the recall, the destruction of product inventory, competitive reaction and consumer attitudes. Even if a product liability or consumer fraud claim is unsuccessful or without merit, the negative publicity surrounding such assertions regarding our products could adversely affect our reputation and brand image. We also could be adversely affected if consumers in our principal markets lose confidence in the safety and quality of our products.

***The consolidation of retail customers could adversely affect us.***

Retail customers in our major markets, may consolidate, resulting in fewer customers for our business. Consolidation also produces larger retail customers that may seek to leverage their position to improve their profitability by demanding improved efficiency, lower pricing, increased promotional programs, or specifically tailored products. In addition, larger retailers have the scale to develop supply chains that permit them to operate with reduced inventories or to develop and market their own white-label brands. Retail consolidation and increasing retailer power could adversely affect our product sales and results of operations. Retail consolidation also increases the risk that adverse changes in our customers' business operations or financial performance will have a corresponding material and adverse effect on us. For example, if our customers cannot access sufficient funds or financing, then they may delay, decrease, or cancel purchases of our products, or delay or fail to pay us for previous purchases, which could materially and adversely affect our product sales, financial condition, and operating results.

***Evolving tax, environmental, food quality and safety or other regulations or failure to comply with existing licensing, labeling, trade, food quality and safety and other regulations and laws could have a material adverse effect on our consolidated financial condition.***

Our activities or products, both within and outside of the United States, are subject to regulation by various



federal, state, provincial and local laws, regulations and government agencies, including the U.S. Food and Drug Administration, U.S. Federal Trade Commission, the U.S. Departments of Agriculture, Commerce and Labor, as well as similar and other authorities outside of the United States, International Accords and Treaties and others, including voluntary regulation by other bodies. In addition, legal and regulatory systems in emerging and developing markets may be less developed, and less certain. These laws and regulations and interpretations thereof may change, sometimes dramatically, as a result of a variety of factors, including political, economic or social events. The manufacturing, marketing and distribution of food products are subject to governmental regulation that control such matters as food quality and safety, ingredients, advertising, product or production requirements, labeling, import or export of our products or ingredients, relations with distributors and retailers, health and safety, the environment, and restrictions on the use of government programs to purchase certain of our products. We are also regulated with respect to matters such as licensing requirements, trade and pricing practices, tax, anticorruption standards, advertising and claims, and environmental matters. The need to comply with new, evolving or revised tax, environmental, food quality and safety, labeling or other laws or regulations, or new, or changed interpretations or enforcement of existing laws or regulations, may have an adverse effect on our business and results of operations. Further, if we are found to be out of compliance with applicable laws and regulations in these areas, we could be subject to civil remedies, including fines, injunctions, termination of necessary licenses or permits, or recalls, as well as potential criminal sanctions, any of which could have an adverse effect on our business. Even if regulatory review does not result in these types of determinations, it could potentially create negative publicity or perceptions which could harm our business or reputation.

***Significant additional labeling or warning requirements may inhibit sales of affected products.***

Various jurisdictions may seek to adopt significant additional product labeling or warning requirements relating to the content or perceived adverse health consequences of our product(s). If these types of requirements become applicable to our product(s) under current or future environmental or health laws or regulations, they may inhibit sales of such products.

## **BUSINESS**

### **Description of the Business**

We are a cannabis products company and lifestyle brand that curates, designs and sells a variety of products for cannabis consumers. We will produce revenue through licensing, packaging and product sales.

### **Business Plan**

The Company is committed to normalizing and simplifying cannabis use through development of the Jane West brand. Jane West, is a voice for mainstream consumers and women like her who stand to benefit greatly from an alternative to alcohol and pharmaceuticals. She believes that cannabis is the best alternative and showcases her cannabis lifestyle through traditional and social media. Jane West is also a product expert, offering branded glass and the Company's proprietary products (the "Collection") to those looking to elevate their cannabis experience with products that seamlessly integrate into a well styled life. In legal markets, Jane West will work with licensed cultivators and processors to select cannabis varieties that may be branded DAY or NIGHT in Jane West packaging. This approach simplifies the consumers buying decision in the dispensary and also offers packaging with a product recommended by Jane West for day or night. We started with pre-rolls and are developing recipes or processes for other delivery forms which may include edibles, tinctures, topicals and vape products. The Company's business strategy leverages its brand, trade secrets and ability to design, develop and distribute functional well-designed cannabis accessories to provide customers with simplified, normalized and seamless integration of cannabis into their active lives.

### **History of the Business**

One day, as Colorado prepared to roll out its recreational cannabis program, a career woman and suburban mom had an idea. Why not incorporate the substance she enjoyed into the dinner parties she hosted for her friends? In a matter of months, the Company's Founder adopted "Jane West" as her nom de plume and was hosting cannabis events that put the plant in a sophisticated, social setting. The events started selling out, and the national and international media were soon writing about this exciting new idea as a reflection of Colorado's closely watched, fledgling legalization program.

Prior to launching her consumption-friendly cannabis events company Edible Events in 2014, Jane was a working mother rising through the management ranks as a corporate event planner. After her employer spotted her vaping on CNBC, she was quickly fired. Jane took this opportunity to fully immerse and invest herself in the cannabis industry full time. She founded Women Grow, the cannabis industry's largest professional networking organization, and Pistil & Pollen (March 16, 2016) to build her eponymous cannabis lifestyle brand Jane West where she develops accessories and home goods that invite mainstream women to experience the benefits of cannabis and take part in the legal lifestyle.

Since inception in March of 2016 the Company has accomplished the following milestones:

Raised \$125,000 from two angel investors to set up the initial corporate structure, hire Pollen Design as the proprietary product designer and begin building an ecommerce site.

Raised \$970,000 from thirteen investors at a \$6M valuation 2016-2018 in order to:

- Build out a more robust legal structure.
- Initiate trademark filings to protect the Jane West name and mark in a variety of classes.
- Acquire general liability insurance.
- Hire Amy Dannemiller as CEO.
- Retained Verdant Communications as the Company's public relations team to handle all the incoming media and event inquiries.
- Added consultants where necessary to help with CFO roles, sales, videos, photo shoots and fulfillment.
- Developed, refined and manufactured the Collection with initial quantities landing in the US in December in time to sell 412 units on Touch of Modern for Christmas 2017.
- Launched and supported glass sales with GRAV (29 SKUS in total) through GRAVs distribution network. From December 2016 through December 2017 there were 9,315 pieces of glass sold with the following distribution by product.
- Started fulfilling orders from sales to distributors, retailers and e-commerce consumers from a fulfillment center in Colorado with \$15,598.44 in proprietary product sales from November 26, 2017 to January 18, 2018.
- Built out the Company's customer relationship management platform with 1000s of businesses entered, developed sales team standard operating procedures, call scripts and training materials to scale as we expand into new markets.

- Launched packaging sales for pre-rolls in Colorado. The Company's packaging contains carefully selected flower branded DAY and NIGHT which is sold into the market by a 100% female owned and operated facility in Lafayette, CO.

Raised \$201,000 from nine investors at a \$10M valuation 2018-2019 in order to:

- Expand Packaging partnerships to 10 states.
- Develop, market, purchase inventory, and distribute CBD Coffee in customized Light & Dark Roasts.
- Market, purchase inventory, and distribute CBD Capsules in customized Day & Night formulations.
- Expand Packaging partnerships to 10 states.
- Strengthen our value proposition to Packaging partners by providing joint tips in addition to packaging.
- Recruit and hire VP of Sales.
- Hire independent consultant as Compliance Officer.
- Built out the Company's customer relationship management platform with hundreds of new businesses entered, developed advanced sales team standard operating procedures, call scripts and training materials adapted to new markets.

2018 Raised \$187,017 in a SAFE Agreement on equity crowdfunding platform Republic.co

- Purchase Travel Collection Inventory
- Launch Branded child resistant packaging sales
- Company Overhead

2020 Raised \$329,182 in a SAFE Agreement on equity crowdfunding platform Republic.co

- Design and launch new glassware line with 17 new products
- expand packaging sales to Canada across five provinces
- Company Overhead

2021 Raised \$205,000 in a SAFE Agreement on equity crowdfunding platform Republic.co

- inventory of new glassware line
- inventory of new Everyday line
- Company Overhead

### The Company's Products and/or Services

| Product / Service     | Description                                   | Current Market                          |
|-----------------------|---|---|
| Glass accessories     | Beaker, Bubbler, Taster, Steamroller and Bowl | Consumers in the global cannabis market |
| The Travel Collection | Compact, Classic, Solo & Wand                 | Consumers in the global cannabis market |

|                           |   |   |
|---------------------------|---|---|
| DAY & NIGHT Capsules      | Supplements   | Consumers in the global hemp market     |
| LIGHT & DARK Coffee       | Coffee  | Consumers in the global hemp market     |
| Child Resistant Packaging | ASTM, CPSC Child-Resistant packaging for cannabis consumables | Currently signed partners in 13 states. |

|              |  |                                     |
|--------------|--|-------------------------------------|
| Hemp         | Hemp flower in bulk tins and mini joints | Consumers in the global hemp market |
| Hemp Topical | .5g Topical Stick                        | Consumers in the global hemp market |
| Merchandise  | Hats, Posters, Koozies                   | Consumers supporting the brand      |

We are constantly researching and developing new accessory and packaging products we think might appeal to our customers. We currently offer over 30 product accessory SKUs and anticipate expanding this number through offering additional collaborations of glass and new proprietary product finishes. Packaging sales are expected to expand from into other legal markets and intellectual property may be developed in the form of recipes for edibles, tinctures, topicals and the other similar offerings that would launch into markets through licensing and packaging agreements.

The Company employs a variety of direct distribution channels, such as third -party wholesalers, retailers and online retailers.

## Competition

The Company competes with other cannabis accessory makers such as PAX and artisans of hand crafted accessories. Additionally, the Company may compete more broadly with cannabis brands such as Willie's Reserve, Marley Natural, van der Pop that market flower and limited accessories. GRAV, while the Company's glass partner is also a competitor as one of the largest precision glass companies offering products suitable for use with cannabis.

The US markets in which the Company's products are sold differ based on the dynamics of each state. For instance, the Company's products may be sold in medical and/ or recreational dispensaries for use by legal cannabis consumers. Additionally, the Company's products may be used to smoke herbs in markets that do not include cannabis dispensaries. In these markets, the Company's products may be sold in local smoke shops or other specialized gift retailers. The Company's products may compete against similar products produced by artisans in local markets. We are not aware of any large global competitors. In many of the markets and industry segments in which we sell the Company's products, we compete against limited branded products and dispensary private -label offerings. We are well positioned in the industry segments and markets in which we operate, and seek to hold a leadership or significant market share position. Product quality, performance, value and packaging are also important differentiating factors.

## Supply Chain and Customer Base

Glass products are supplied by GRAV. The Company generates licensing revenue related to GRAV sales of JW branded accessories. Additionally, the Company may hold inventory of GRAV produced glass to offer direct to retailer or consumers with whom the Company has a relationship. The Company relies on its relationship with GRAV to offer the signature glass products. The Company's Collection is designed by

Greenlane Pollen Gear and produced abroad under the joint supervision of the Company and Greenlane Pollen Gear. The Company owns all designs and may move manufacturing to a number of other facilities if necessary. Collection product packaging is purchased through the Company's manufacturing relationships abroad. Other packaging related to ASTM, CPSC Child-Resistant packaging is purchased from Greenlane Pollen Gear. In the event Greenlane Pollen Gear was unable to sell the Company packaging, other vendors exist.

The Company is dependent on the following suppliers:

| Supplier or Description               | Service, input or raw material provided  | Percent of such service, input or raw material from such supplier |
|---------------------------------------|--|---|
| Greenlane Pollen Gear                 | ASTM, CPSC Child-Resistant Packaging     | 100.0%  |
| Valiant Distribution Canada Inc.      | Homegoods, accessories, glassware        | 100.0%  |
| PRE-PACKS, LLC                        | Packaging, Glass Container Manufacturing | 100.0%  |
| Steepfuze, LLC                        | Coffee                                   | 100.0%  |
| Life-N-Living                         | Travel Collection Manufacturing          | 100.0%  |
| Kush Supply Co                        | Custom Joint Tips                        | 100.0%  |
| WHT LBL                               | Handrolled Hemp Mini Joints              | 100.0%  |
| Elmore Mountain Therapeutics Topicals | Travel Stick 100 mg CBD                  | 100.0%  |


The Company's customers include distributors, smoke shops, dispensaries, e-commerce stores and individual consumers.

## Intellectual Property

### Trademarks

| Owner             | Country | Trademark – Class(es) | Status  | App. No.  | App. Date  | Reg. No. | Reg. Date | Goods/Services   |
|-------------------|---------|-----------------------|---------|-----------|------------|----------|-----------|--|
| Triple Dutch, LLC | CA      | JW - 34               | Pending | 1905354   | 06/20/2018 |          |           | Smoking pipes; Snuff dispensers; Tobacco water pipes; Electronic cigarette cases; Electronic cigarette holders; Electronic cigarettes; Oral vaporizers for smoking purposes. |
| Triple Dutch, LLC | EM      | JANE WEST - 34/35/41  | Opposed | 016782948 | 05/30/2017 |          |           | Electronic cigarette cases; Electronic cigarette holders;  |

|                   |    |                       |            |           |            |          |             |  |
|-------------------|----|-----------------------|------------|-----------|------------|----------|-------------|--|
|                   |    |                       |            |           |            |          |             | Electronic cigarettes; Oral vaporizers for smoking purposes; Smoking pipes; Snuff dispensers; Tobacco water pipes; smokers' articles.; Advertising services, namely, promoting the brands, goods and services of others; Endorsement services, namely, promoting the goods and services of others; advertising, marketing and promotional services; Providing information, news and commentary in the field of entertainment, pop culture and recreation and leisure activities; entertainment services, namely, personal appearances by an entrepreneur and business woman; entertainment and educational services; organization of seminars, workshops, conferences. |
| Triple Dutch, LLC | US | CANNABIS CLEANSE - 44 | Registered | 87227 178 | 11/04/2016 | 5318 958 | 10/24 /2017 | Providing information in the field of alternative health and healing, wellness and nutrition.  |
| Triple Dutch, LLC | US | JANE WEST - 34        | Allowed    | 87252 341 | 11/30/2016 |          |             | Electronic cigarette cases; Electronic cigarette holders; Electronic cigarettes; Oral vaporizers for smoking purposes; Smoking pipes; Snuff dispensers; Tobacco water pipes.   |

|                   |    |  |            |           |            |          |            |  |
|-------------------|----|--|------------|-----------|------------|----------|------------|--|
| Triple Dutch, LLC | US | JANE WEST - 34   | Allowed    | 87979 819 | 11/30/2016 |          |            | Oral vaporizers for smoking purposes; Smoking pipes; Snuff dispensers.   |
| Triple Dutch, LLC | US | JANE WEST - 35   | Registered | 87252 365 | 11/30/2016 | 5566 407 | 09/18/2018 | Advertising services, namely, promoting the brands, goods and services of others; endorsement services, namely, promoting the goods and services of others.  |
| Triple Dutch, LLC | US | JANE WEST - 41   | Registered | 87252 372 | 11/30/2016 | 5566 408 | 09/18/2018 | Providing information, news and commentary in the field of entertainment, pop culture and recreation and leisure activities; entertainment services, namely, personal appearances by an entrepreneur and business woman.                               |
| Triple Dutch, LLC |    | <br>("JANE WEST (Stylized)") - 35 | Registered | 87001 996 | 4/15/2016  | 5661 846 | 1/22/2019  | On-line retail store services featuring a wide variety of consumer goods of others   |
| Triple Dutch, LLC | US | JW - 20  | Pending    | 88202 931 | 11/21/2018 |          |            | Packaging containers of plastic.   |
| Triple Dutch, LLC | US | JW - 21  | Pending    | 8820 2973 | 11/21/2018 |          |            | Beverageware; Containers for household or kitchen use; Servingware for serving food and drinks; Household storage containers for food; Graters for household purposes; hand operated kitchen grinders; non-electric French press; non-electric kettle. |
| Triple Dutch, LLC | US | JW - 30  | Pending    | 88202 989 | 11/21/2018 |          |            | Coffee; tea.   |

|                   |    |         |         |           |             |  |  |  |
|-------------------|----|---------|---------|-----------|-------------|--|--|--|
| Triple Dutch, LLC | US | JW - 34 | Pending | 87731 259 | 12/21/ 2017 |  |  | Electronic cigarette cases; Electronic cigarette holders; Electronic cigarettes; Oral vaporizers for smoking purposes; Smoking pipes; Snuff dispensers; Tobacco water pipes. |
| Triple Dutch, LLC | US | JW - 5  | Pending | 88202 897 | 11/21 /2018 |  |  | Nutritional supplements in capsule form and liquid form.   |

### Governmental/Regulatory Approval and Compliance

The Company is subject to and affected by laws and regulations of U.S. federal, state and local governmental authorities and may be subject to the laws and regulations of international countries and bodies, such as the European Union (the "EU") to the extent sales are activated in these territories. These laws and regulations are subject to change.

### Litigation

None

### Other

The Company's principal address is 5082 East Hampden Avenue, Suite 242, Denver, CO 80222.

The Company does not have any additional addresses.

The Company conducts business in Colorado.

The following companies are wholly owned subsidiaries of the Company:

| Name               | Entity Type               | Location of Formation | Date of Formation | % Owned by Company |
|--------------------|---------------------------|-----------------------|-------------------|--------------------|
| JW Homegoods, LLC  | Limited Liability Company | Delaware              | October 27, 2016  | 100.0%             |
| Electric Feel, LLC | Limited Liability Company | Delaware              | October 17, 2016  | 100.0%             |
| Her Goods, LLC     | Limited Liability Company | Delaware              | October 17, 2016  | 100.0%             |
| Triple Dutch, LLC  | Limited Liability Company | Delaware              | October 17, 2016  | 100.0%             |
| Level Twelve, LLC  | Limited Liability Company | Delaware              | May 4, 2019       | 100.0%             |



## DIRECTORS, OFFICERS, AND MANAGERS

The directors, officers, and managers of the Company are listed below along with all positions and offices held at the Company and their principal occupation and employment responsibilities for the past three (3) years.

| Name            | Positions and Offices Held at the Company | Principal Occupation and Employment Responsibilities for the Last Three (3) Years   | Education  |
|-----------------|---|---|--|
| Amy Dannemiller | Manager and CEO                           | Founder, Chairwoman, Women Grow (2014-2017)   | MSW, Denver University<br>BS, International Relations, University of Wisconsin   |
| Scot Crow       | Manager                                   | Scot Crow is Member and Practice Department Manager: Corporate, M&A, Private Equity, Securities and Tax of Dickinson Wright PLLC. | B.S., Franciscan University<br>J.D. Capital University Law School, Order of the Curie LL.M., Taxation, Capital University Ohio Bar |

### *Indemnification*

Indemnification is authorized by the Company to managers, officers or controlling persons acting in their professional capacity pursuant to Delaware law. Indemnification includes expenses such as attorney's fees and, in certain circumstances, judgments, fines and settlement amounts actually paid or incurred in connection with actual or threatened actions, suits or proceedings involving such person, except in certain circumstances where a person is adjudged to be guilty of gross negligence or willful misconduct, unless a court of competent jurisdiction determines that such indemnification is fair and reasonable under the circumstances.

### **Employees**

The Company currently has 2 employees. The Company has the following employment/labor agreement in place:

| Employee | Description | Effective Date | Termination Date |
|----------|-------------|----------------|------------------|
|----------|-------------|----------------|------------------|

|               |                         |               |               |
|---------------|-------------------------|---------------|---------------|
| Kate Csillagi | Employment<br>Agreement | April 1, 2019 | April 1, 2022 |
|---------------|-------------------------|---------------|---------------|

*[Remainder of Page Intentionally Left Blank]*

## CAPITALIZATION AND OWNERSHIP

### Capitalization

The Company has issued the following outstanding Securities:

|   |   |
|---|---|
| <b>Type of security</b>   | Class A-1 LLC/Membership Interests  |
| <b>Amount outstanding</b>   | 750,000   |
| <b>Voting Rights</b>  | Certain voting rights with Board Representation   |
| <b>Anti-Dilution Rights</b>   | Founders units with anti-dilution protection until \$2mm in aggregate proceeds raised.  |
| <b>How this Security may limit, dilute or qualify the Notes/Bonds issued pursuant to Regulation CF</b>  | These securities will represent no less than 12.5% of the Company until \$2mm in equity capital raised which will mean that Class B, Class C (profits interest) and SAFE will be diluted by a percentage higher than the As in the short run. |
| <b>Percentage ownership of the Company by the holders of such security (assuming conversion prior to the Offering if convertible securities).</b> | 11.6%   |

|   |   |
|---|---|
| <b>Type of security</b>   | Class A-2 LLC/Membership Interests  |
| <b>Amount outstanding</b>   | 750,000   |
| <b>Voting Rights</b>  | Certain voting rights with Board Representation   |
| <b>Anti-Dilution Rights</b>   | Founders units with anti-dilution protection until \$2mm in aggregate proceeds raised.  |
| <b>How this Security may limit, dilute or qualify the Notes/Bonds issued pursuant to Regulation CF</b>  | These securities will represent no less than 12.5% of the Company until \$2mm in equity capital raised which will mean that Class B, Class C (profits interest) and SAFE will be diluted by a percentage higher than the As in the short run. |
| <b>Percentage ownership of the Company by the holders of such security (assuming conversion prior to the Offering if convertible securities).</b> | 11.6%   |

|                         |                                  |
|-------------------------|----------------------------------|
| <b>Type of security</b> | Class B LLC/Membership Interests |
|-------------------------|----------------------------------|

|   |  |
|---|--|
| <b>Amount outstanding</b>   | 1,106,144  |
| <b>Voting Rights</b>  | Board representation controlled by majority holder of the Class B units  |
| <b>Anti-Dilution Rights</b>   | <p>To the extent that the Company issues any Remaining Class B Membership Units, Units or other equity in the Company (collectively “New Units”) (other than any issuance pursuant to (i) the sellers of a company or a business (or any related assets) acquired by or merged with the Company as part or all of the acquisition; (ii) any additional Class B Membership Units issued pursuant to the Company’s agreements; or (iii) any employee incentive plan that has been adopted by the Company)) and the purchase price per Unit is less than \$1.66 (as determined without regard to the operation of the Company’s agreements and the issuance of Adjusting Units), as adjusted (a “Dilutive Transaction”), contemporaneously with the Dilutive Transaction, (i) the Company will issue to each of the Class B Members additional Class B Membership Units in the Company in an amount which provides them with the Percentage Interest which they would have held in the Company represented by the Units purchased by them on date of the Dilutive Transaction, had the New Units been sold at \$1.66 per Unit, as Adjusted (“Adjusting Units”) ) and (ii) the number of Remaining Units Class B Units available for purchase by the Class B Members pursuant to the Company’s agreements shall be increased to an amount which would provide each Class B Member with the Percentage Interest (upon exercise of an Option) which they would have held in the Company represented by the Units available for purchase by them on date of the Dilutive Transaction, had the New Units been sold at \$1.66 per Unit.</p> |
| <b>How this Security may limit, dilute or qualify the Notes/Bonds issued pursuant to Regulation CF</b>  | N/A  |
| <b>Percentage ownership of the Company by the holders of such security (assuming conversion prior to the Offering if convertible securities).</b> | 17.2%  |
| <b>Type of security</b>   | Class C LLC/Membership Interests   |

|   |                |
|---|----------------|
| <b>Amount outstanding</b>   | 3,299,995      |
| <b>Voting Rights</b>  | None           |
| <b>Anti-Dilution Rights</b>   | None           |
| <b>How this Security may limit, dilute or qualify the Notes/Bonds issued pursuant to Regulation CF</b>  | Not Applicable |
| <b>Percentage ownership of the Company by the holders of such security (assuming conversion prior to the Offering if convertible securities).</b> | 51.3%          |

|   |  |
|---|--|
| <b>Type of security</b>   | Units of Crowd SAFE (Simple Agreement for Future Equity) |
| <b>Amount outstanding</b>   | 721,199  |
| <b>Voting Rights</b>  | None   |
| <b>Anti-Dilution Rights</b>   | None   |
| <b>How this Security may limit, dilute or qualify the securities issued pursuant to Regulation CF</b> | N/A  |

As of December 31, 2020, the company has Accounts Payable of \$294,924 due to vendors (including Legal and Professional Fees) and \$320,393 in Deferred Wages due to Amy Dannemiller. Otherwise, the company does not have any third-party debt outstanding.

### **Ownership**

The Company is held by twenty (22) members. The largest holder is an entity owned and controlled by Founder Amy Dannemiller.

Below are the beneficial owners of 20% percent or more of the Company's outstanding units.

|                 |                         |
|-----------------|-------------------------|
| <b>Name</b>     | <b>Percentage Owned</b> |
| Amy Dannemiller | 51%                     |

*[Remainder of Page Intentionally Left Blank]*

## **FINANCIAL INFORMATION**

**Please see the financial information listed on the cover page of this Form C-AR and attached hereto in addition to the following information. Financial statements are attached hereto as Exhibit A.**

### **Operations**

Pistil & Pollen, LLC (“the Company”) was incorporated on March 16, 2016 under the laws of the State of Delaware, and is headquartered in Denver, Colorado. The Company was formed to assume and develop the business of Jane West, LLC, formed January 5, 2014 by Amy Dannemiller, related to brand and product development around the “Jane West” name and marks.

### **Liquidity and Capital Resources**

The Company considers all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. As of January 1, 2021, the Company had \$95,697 cash on hand, with a burn rate of approximately \$25,000. The Company has recurring revenue from its packaging partners that is anticipated in Q1 of 2021 and every subsequent quarter the Company’s revenue in packaging partnerships grows. Additionally, the Company just closed a deal with a 21 chain store in Colorado and will receive a record high \$6/unit for that deal which will see the Company receiving monthly pay-outs beginning late Q1. Additional sales events are planned and deals are being worked out for Q1 and Q2 of 2021.

The funds will continue to be used to execute the Company’s business strategy.

### **Capital Expenditures and Other Obligations**

The Company intends to make the following material capital expenditures in the future: The Company will acquire proprietary product inventory on a rolling monthly basis. In aggregate this represents a commitment of approximately \$50,000. This number includes shipping costs related to such inventory purchases.

Pursuant to a design agreement with a Supplier, the Company will pay royalties of 5% capped at \$25,000 per proprietary product.

### **Valuation**

The Company has ascribed no pre-offering valuation to the Company; the securities are priced arbitrarily.

### **Trends and Uncertainties**

After reviewing the above discussion of the steps the Company intends to take, potential Purchasers should consider whether achievement of each step within the estimated time frame is realistic in their judgment. Potential Purchasers should also assess the consequences to the Company of any delays in taking these steps and whether the Company will need additional financing to accomplish them.

The financial statements are an important part of this Form C-AR and should be reviewed in their entirety. The financial statements of the Company are attached hereto as Exhibit A.

### **Authorized Capitalization**

At the initial closing of this Offering (if the minimum amount is sold), we will have membership interests outstanding.

The Company has offered up to 535,000 of Units of SAFE (Simple Agreement for Future Equity) for up to \$535,000.00. The Company is attempting to raise a minimum amount of \$25,000.00 in this Offering (the "Minimum Amount"). The Company must receive commitments from investors in an amount totaling the Minimum Amount by April 21, 2020 (the "Offering Deadline") in order to receive any funds. If the sum of the investment commitments does not equal or exceed the Minimum Amount by the Offering Deadline, no Securities will be sold in the Offering, investment commitments will be cancelled and committed funds will be returned to potential investors without interest or deductions.

The Securities are not currently equity interests in the Company and can be thought of as the right to receive equity at some point in the future upon the occurrence of certain events.

### Other Material Terms

- The Company does not have the right to repurchase the securities issued pursuant Regulation CF.
- The securities issued pursuant Regulation CF do not have a stated return or liquidation preference.
- The Company cannot determine if it currently has enough capital stock authorized to issue upon the conversion of the securities issued pursuant Regulation CF, because the amount of capital stock to be issued is based on the occurrence of future events.

### Previous Offerings of Securities

In addition to this present offering under Regulation CF, we have made the following issuances of securities within the last three years:

| Security Type             | Number Sold | Money Raised | Use of Proceeds      | Offering Date      | Exemption from Registration Used or Public Offering |
|---------------------------|-------------|--------------|----------------------|--------------------|---|
| LLC/ Membership Interests | 125,000     | \$125,000.00 | Formation            | March 16, 2016     | Rule 506(b)   |
| LLC/Member ship Interests | 970,000     | \$970,000.00 | Start-up operations  | September 1, 2016  | Rule 506(b)   |
| Units of Crowd SAFE       | 187,017     | \$187,017.00 | Continued Operations | January 26, 2018   | Regulation CF                                       |
| LLC/Member ship Interests | 106,024     | \$176,000.00 | Start-up operations  | May 1, 2018        | Rule 506(b)   |
| Units of Crowd SAFE       | 329,182     | 329,182.88   | Continued Operations | January 14th, 2020 | Regulation CF                                       |
| Units of Crowd SAFE       | 205,000     | 205,000.00   | Continued Operations | March 6th, 2021    | Regulation CF                                       |

## **Restrictions on Transfer**

Any Securities sold pursuant to Regulation CF being offered may not be transferred by any Purchaser of such Securities during the one-year holding period beginning when the Securities were issued, unless such Securities are transferred: 1) to the Company, 2) to an accredited investor, as defined by Rule 501(a) of Regulation D promulgated under the 1933 Act, 3) as part of an IPO or 4) to a member of the family of the Purchaser or the equivalent, to a trust controlled by the Purchaser, to a trust created for the benefit of a member of the family of the Purchaser or the equivalent, or in connection with the death or divorce of the Purchaser or other similar circumstances. "Member of the family" as used herein means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother/father/daughter/son/sister/brother-in-law, and includes adoptive relationships. Remember that although you may legally be able to transfer the Securities, you may not be able to find another party willing to purchase them.

In addition to the foregoing restrictions, prior to making any transfer of the Securities or any Securities into which they are convertible, such transferring Purchaser must either make such transfer pursuant to an effective registration statement filed with the SEC or provide the Company with an opinion of counsel stating that a registration statement is not necessary to effect such transfer.

## **TRANSACTIONS WITH RELATED PERSONS AND CONFLICTS OF INTEREST**

### **Related Person Transactions**

From time to time the Company may engage in transactions with related persons. Related persons are defined as any manager or officer of the Company; any person who is the beneficial owner of 10 percent or more of the Company's outstanding voting equity securities, calculated on the basis of voting power; any promoter of the Company; any immediate family member of any of the foregoing persons or an entity controlled by any such person or persons.

As of March 31, 2021, Amy Dannemiller loaned the company \$33,775 for the purchase of inventory. The loan is expected to be repaid in Q2 2021. In March 2020, an immediate family member of Amy Dannemiller loaned the company \$25,000. The loan was repaid in April of 2020. As of December 31, 2019, there were no loans outstanding between related persons.

As of December 31, 2021, Amy Dannemiller is entitled to deferred compensation through Electric feel, LLC, a wholly owned subsidiary of Pistil & Pollen, LLC, in the amount of \$320,393.

### **Conflicts of Interest**

The Company has not engaged in any transactions or relationships, which may give rise to a conflict of interest with the Company, its operations or its security holders.

## **OTHER INFORMATION**

None

### **Bad Actor Disclosure**



None

## SIGNATURE

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.

|  |                         |
|--|-------------------------|
|  | /s/ Amy Dannemiller     |
|  | (Signature)             |
|  |                         |
|  | Amy Dannemiller         |
|  | (Name)                  |
|  |                         |
|  | Chief Executive Officer |
|  | (Title)                 |

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), this Form C has been signed by the following persons in the capacities and on the dates indicated.

|  |                     |
|--|---------------------|
|  | /s/ Amy Dannemiller |
|  | (Signature)         |
|  |                     |
|  | Amy Dannemiller     |
|  | (Name)              |
|  |                     |
|  | Manager             |
|  | (Title)             |
|  |                     |
|  | April 30, 2020      |
|  | (Date)              |

|  |                |
|--|----------------|
|  | /s/ Scot Crow  |
|  | (Signature)    |
|  |                |
|  | Scot Crow      |
|  | (Name)         |
|  |                |
|  | Manager        |
|  | (Title)        |
|  |                |
|  | April 30, 2020 |
|  | (Date)         |

**EXHIBIT A**  
*Financial Statements*

**PISTIL & POLLEN, LLC**

**Unaudited Consolidated Balance Sheet and Unaudited Consolidated Statement of Operations  
for the Fiscal Year Ended December 31, 2020**

**PISTIL & POLLEN, LLC**  
**CONSOLIDATED BALANCE SHEET**  
**December 31, 2020**  
**(Unaudited)**

**ASSETS**

Current assets

|                           |                |
|---------------------------|----------------|
| Cash and cash equivalents | \$ 95,697      |
| Accounts receivable       | 25,452         |
| Prepaid expenses          | 17,596         |
| Inventory                 | <u>167,290</u> |

Total current assets 306,035

|                             |                 |
|-----------------------------|-----------------|
| Property and equipment      | 43,250          |
| Accumulated depreciation    | <u>(43,250)</u> |
| Property and equipment, net | -               |

Intangible assets

|            |                |
|------------|----------------|
| Trademarks | <u>168,356</u> |
|------------|----------------|

Total assets \$ 474,391

**LIABILITIES AND MEMBERS' CAPITAL**

Current liabilities

|                   |                |
|-------------------|----------------|
| Accounts payable  | \$ 294,924     |
| Accrued expenses  | 44,440         |
| Customer deposits | 21,414         |
| Deferred wages    | <u>320,393</u> |

Total current liabilities 681,171

**MEMBERS' CAPITAL**

|  |                    |
|--|--------------------|
| Members' capital, contributions net of distributions | 1,411,898          |
| Additional paid-in capital                           | 450,001            |
| Accumulated deficit                                  | <u>(2,068,679)</u> |

Total members' capital (deficit) (206,780)

Total liabilities and members' capital \$ 474,391

**PISTIL & POLLEN, LLC**  
**CONSOLIDATED STATEMENTS OF**  
**OPERATIONS**  
**Year Ended December 31, 2020**

|                            |                |
|----------------------------|----------------|
| Revenues                   | \$ 369,193     |
| Cost of revenues           | <u>191,004</u> |
| Gross profit               | 178,189        |
| Operating expenses         |                |
| General and administrative | 423,068        |
| Sales and marketing        | 39,573         |
| Depreciation expense       | <u>12,014</u>  |
| Total operating expenses   | 474,655        |
| Net operating loss         | (296,466)      |
| Other expenses             |                |
| Other expenses             | <u>0</u>       |
| Total other expenses       | <u>0</u>       |
| Net loss                   | \$ (296,466)   |

**Pistil & Pollen, LLC and Subsidiaries**

**Consolidated Financial Statements  
and Independent Accountant's Review Report**

**December 31, 2019 and 2018**

---

**Pistil & Pollen, LLC and  
Subsidiaries**

**Index**

|   | <b><u>Page</u></b> |
|---|--------------------|
| Independent Accountant's Review Report                | 2                  |
| Consolidated Financial Statements                     |                    |
| Consolidated Balance Sheets                           | 4                  |
| Consolidated Statements of Operations                 | 5                  |
| Consolidated Statements of Members' Capital (Deficit) | 6                  |
| Consolidated Statements of Cash Flows                 | 7                  |
| Notes to Consolidated Financial Statements            | 8                  |

## Independent Accountant's Review Report

To the Board of Managers  
Pistil & Pollen, LLC and Subsidiaries

We have reviewed the accompanying consolidated financial statements of Pistil & Pollen, LLC and Subsidiaries, which comprise the consolidated balance sheets as of December 31, 2019, and the related consolidated statements of operations, members' capital (deficit), and cash flows for the year then ended, and the related notes to the consolidated financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of company management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the consolidated financial statements as a whole. Accordingly, we do not express such an opinion.

### *Management's Responsibility for the Consolidated Financial Statements*

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement whether due to fraud or error.

### *Accountant's Responsibility*

Our responsibility is to conduct the review engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the consolidated financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our conclusion.

### *Accountant's Conclusion*

Based on our review, we are not aware of any material modifications that should be made to the consolidated financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America.

### *Report on 2018 Consolidated Financial Statements*

The consolidated financial statements of Pistil & Pollen, LLC and Subsidiaries as of December 31, 2018, prior to adjustment, were reviewed by other independent accountants whose report dated January 3, 2020, stated that based on their procedures, they were not aware of any material modifications should be made in order for them to be in accordance with accounting principles generally accepted in the United States of America.



*Report on Restatement Adjustments to 2018 Financial Statements*

As part of our review of the 2019 consolidated financial statements, we also reviewed the adjustments described in Note 3 that were applied to restate the 2018 financial statements. Based on our review, we are not aware of any material modifications that should be made to the adjustments that were applied to restate the 2018 consolidated financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America.

*Emphasis of Matter Regarding Going Concern*

The accompanying consolidated financial statements have been prepared assuming that Pistil & Pollen, LLC and Subsidiaries will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, since inception, the Company has relied on member capital to fund its operations. As of December 31, 2019, the Company has not reached profitability and will likely incur additional losses prior to generating positive cash flow from operations. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's evaluation and plans regarding these matters are also discussed in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our conclusion is not modified with respect to this matter.

A handwritten signature in black ink that reads "CohnReznick LLP".

Baltimore, Maryland

March 1, 2021

**Pistil & Pollen, LLC and Subsidiaries**

**Consolidated Balance Sheets  
December 31, 2019 and 2018**

|  | 2019         | 2018         |
|--|--------------|--------------|
| Current assets                                       |              |              |
| Cash and cash equivalents                            | \$ 19,481    | \$ 45,380    |
| Accounts receivable                                  | 12,900       | 59,972       |
| Inventory  | 84,356       | 91,387       |
|  | <hr/>        | <hr/>        |
| Total current assets                                 | 116,737      | 196,739      |
|  | <hr/>        | <hr/>        |
| Property and equipment                               | 43,250       | 43,250       |
| Accumulated depreciation                             | (31,236)     | (16,819)     |
| Property and equipment, net                          | 12,014       | 26,431       |
|  | <hr/>        | <hr/>        |
| Other assets   |              |              |
| Trademarks   | 115,837      | 79,132       |
|  | <hr/>        | <hr/>        |
| Total assets   | \$ 244,588   | \$ 302,302   |
|  | <hr/>        | <hr/>        |
| <u>Liabilities and Members' Capital (Deficit)</u>    |              |              |
| Current liabilities                                  |              |              |
| Accounts payable                                     | \$ 196,672   | \$ 130,547   |
| Deferred salaries                                    | 247,476      | 122,476      |
|  | <hr/>        | <hr/>        |
| Total current liabilities                            | 444,148      | 253,023      |
|  | <hr/>        | <hr/>        |
| Total liabilities                                    | 444,148      | 253,023      |
|  | <hr/>        | <hr/>        |
| Members' capital (deficit)                           |              |              |
| Members' capital, contributions net of distributions | \$ 1,411,898 | \$ 1,285,898 |
| Additional paid-in capital                           | 160,755      | 160,755      |
| Accumulated deficit                                  | (1,772,213)  | (1,397,374)  |
|  | <hr/>        | <hr/>        |
| Total members' capital (deficit)                     | (199,560)    | 49,279       |
|  | <hr/>        | <hr/>        |
| Total liabilities and members' capital (deficit)     | \$ 244,588   | \$ 302,302   |
|  | <hr/>        | <hr/>        |

See Independent Accountant's Review Report and Notes to Consolidated Financial Statements.

**Pistil & Pollen, LLC and Subsidiaries**

**Consolidated Statements of Operations**  
**Years Ended December 31, 2019 and 2018**

|                            | <u>2019</u>         | <u>2018</u>         |
|----------------------------|---------------------|---------------------|
| Revenues                   | \$ 202,814          | \$ 204,439          |
| Cost of revenues           | <u>107,275</u>      | <u>97,542</u>       |
| Gross profit               | 95,539              | 106,897             |
| Operating expenses         |                     |                     |
| General and administrative | 430,977             | 418,322             |
| Sales and marketing        | 21,547              | 42,224              |
| Depreciation expense       | <u>14,417</u>       | <u>14,417</u>       |
| Total operating expenses   | <u>466,941</u>      | <u>474,963</u>      |
| Net operating loss         | <u>(371,402)</u>    | <u>(368,066)</u>    |
| Other expenses             |                     |                     |
| Other expenses             | <u>(3,437)</u>      | <u>-</u>            |
| Total other expenses       | <u>(3,437)</u>      | <u>-</u>            |
| Net loss                   | <u>\$ (374,839)</u> | <u>\$ (368,066)</u> |

See Independent Accountant's Review Report and Notes to Consolidated Financial Statements.

**Pistil & Pollen, LLC and Subsidiaries**

**Consolidated Statements of Members' Capital (Deficit)  
Years Ended December 31, 2019 and 2018**

|                                 | <u>Members' capital</u>    | <u>Additional paid-in<br/>capital SAFEs</u> | <u>Accumulated<br/>deficit</u> | <u>Total members'<br/>capital (deficit)</u> |
|---------------------------------|----------------------------|---|--------------------------------|---|
| Balance as of December 31, 2017 | <u>\$ 1,105,897</u>        | <u>\$ -</u>                                 | <u>\$ (1,029,308)</u>          | <u>\$ 76,589</u>                            |
| Member contributions            | 180,001                    | -   | -                              | 180,001                                     |
| Issuance of SAFEs               | -                          | 160,755                                     | -                              | 160,755                                     |
| Net loss                        | <u>-</u>                   | <u>-</u>                                    | <u>(368,066)</u>               | <u>(368,066)</u>                            |
| Balance as of December 31, 2018 | <u>1,285,898</u>           | <u>160,755</u>                              | <u>(1,397,374)</u>             | <u>49,279</u>                               |
| Member contributions            | 126,000                    | -   | -                              | 126,000                                     |
| Net loss                        | <u>-</u>                   | <u>-</u>                                    | <u>(374,839)</u>               | <u>(374,839)</u>                            |
| Balance as of December 31, 2019 | <u><u>\$ 1,411,898</u></u> | <u><u>\$ 160,755</u></u>                    | <u><u>\$ (1,772,213)</u></u>   | <u><u>\$ (199,560)</u></u>                  |

See Independent Accountant's Review Report and Notes to Consolidated Financial Statements.

**Pistil & Pollen, LLC and Subsidiaries**

**Consolidated Statements of Cash Flows**  
**Years Ended December 31, 2019 and 2018**

|  | <u>2019</u>             | <u>2018</u>             |
|--|-------------------------|-------------------------|
| Cash flows from operating activities                                       |                         |                         |
| Net loss   | \$ (374,839)            | \$ (368,066)            |
| Adjustments to reconcile net loss to net cash used in operating activities |                         |                         |
| Depreciation and amortization  | 14,417                  | 14,417                  |
| Changes in operating assets and liabilities                                |                         |                         |
| Accounts receivable  | 47,072                  | (51,237)                |
| Inventory  | 7,031                   | (54,108)                |
| Prepaid expenses   | -                       | 5,930                   |
| Accounts payable   | 66,125                  | 22,616                  |
| Accrued expenses   | -                       | (67)                    |
| Deferred salaries  | <u>125,000</u>          | <u>122,476</u>          |
| Net cash used in operating activities                                      | <u>(115,194)</u>        | <u>(308,039)</u>        |
| Cash flows from investing activities                                       |                         |                         |
| Trademark expenditures   | <u>(36,705)</u>         | <u>(40,630)</u>         |
| Net cash used in investing activities                                      | <u>(36,705)</u>         | <u>(40,630)</u>         |
| Cash flows from financing activities                                       |                         |                         |
| Member contributions   | 126,000                 | 180,001                 |
| Issuance of SAFEs  | <u>-</u>                | <u>160,755</u>          |
| Net cash provided by financing activities                                  | <u>126,000</u>          | <u>340,756</u>          |
| Net decrease in cash and cash equivalents                                  | <u>(25,899)</u>         | <u>(7,913)</u>          |
| Cash and cash equivalents at beginning of year                             | <u>45,380</u>           | <u>53,293</u>           |
| Cash and cash equivalents at end of year                                   | <u><u>\$ 19,481</u></u> | <u><u>\$ 45,380</u></u> |

See Independent Accountant's Review Report and Notes to Consolidated Financial Statements.

## **Pistil & Pollen, LLC and Subsidiaries**

### **Notes to Consolidated Financial Statements Years Ended December 31, 2019 and 2018**

#### **Note 1 - Nature of operations**

##### **Organization and operations**

Pistil & Pollen, LLC (the "Parent") was incorporated on March 16, 2015 in the State of Delaware and was last amended in September 2016. The Parent and its Subsidiaries may be referred to collectively herein as the "Company", "we", "us" or "our". We curate, design, and sell a variety of branded packaging and products for cannabis and hemp consumers. We will produce revenue through royalties, licensing, packaging, and product sales relating to our brands.

##### **Going concern matters**

Since inception, the Company has relied on member capital to fund its operations. As of December 31, 2019, the Company has not reached profitability and will likely incur additional losses prior to generating positive cash flow from operations. These matters raise substantial doubt about the Company's ability to continue as a going concern. The Company intends to fund its operations with proceeds from a crowdfunding campaign (see Note 8) and from the sale of its products including fees earned by licensing the use its trademark to others.

#### **Note 2 - Summary of significant accounting policies**

##### **Basis of presentation**

The consolidated financial statements reflect the accounts of the Company. The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP").

##### **Basis of consolidation**

The financial statements include the consolidated results of JW Homegoods, LLC, Electric Feel, LLC, Triple Dutch, LLC and Her Goods, LLC (collectively, the "Subsidiaries"), which are wholly-owned subsidiaries of the Company. All significant intercompany accounts and transactions have been eliminated in consolidation.

##### **Use of estimates**

The preparation of financial statements in conformity with US GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes thereto. Actual results could materially differ from these estimates. It is reasonably possible that changes in estimates will occur in the near term.

Revisions to accounting estimates are recognized in the period in which the estimates are revised and any future periods affected. The information about significant areas of estimation, uncertainty and judgment considered by management in preparing these consolidated financial statements is as follows:

##### **Estimated useful lives and depreciation of property and equipment**

Depreciation of property and equipment is dependent upon estimates of useful lives, which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that consider factors such as economic and market conditions and useful lives of assets.

## **Pistil & Pollen, LLC and Subsidiaries**

### **Notes to Consolidated Financial Statements Years Ended December 31, 2019 and 2018**

Estimated useful lives are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis.

#### **Risks and uncertainties**

The Company has a limited operating history. The Company's business and operations are sensitive to general business and economic conditions in the United States of America. A host of factors beyond the Company's control could cause fluctuations in these conditions. Adverse conditions may include recession, downturn or otherwise, changes in regulations or restrictions on imports, competition or changes in consumer taste. These adverse conditions could affect the Company's financial condition and the results of its operations. As of December 31, 2019 and 2018, the Company is operating as a going concern. See Note 1 and Note 9 for additional information.

#### **Cash and cash equivalents**

The Company considers short-term, highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Cash consists of funds held in the Company's checking account. The Company maintains its cash with a major financial institution located in the United States of America, which it believes to be credit worthy.

#### **Inventory**

Inventory is comprised of finished goods, accessories and supplies for cannabis and hemp related products and is recorded at the lower of cost or net realizable value and on a first-in, first out basis.

#### **Trademarks**

The Company capitalizes costs related to developing and registering its trademarks, as the Company expects to maintain the use of its trademarks indefinitely. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate they might be impaired. The estimated useful lives, residual values, and amortization methods are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis. Therefore, there is no amortization expense recorded in the consolidated statements of operations.

#### **Receivables and credit policy**

Trade receivables from customers are uncollateralized customer obligations due under normal trade terms. Trade receivables are stated at the amount billed to the customer. Payments of trade receivables are allocated to the specific invoices identified on the customer's remittance advice or, if unspecified, are applied to the earliest unpaid invoice. The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited and it has not experienced significant write-downs in its accounts receivable balances. As of December 31, 2019 and 2018, the Company had \$12,900 and \$59,972 of accounts receivable, stated, respectively.

Accounts receivable are written off when they are deemed to be uncollectible. Any allowance for doubtful accounts is estimated based on the Company's historical amounts written off, existing conditions in the industry, and the financial stability of the customer. As of December

## **Pistil & Pollen, LLC and Subsidiaries**

### **Notes to Consolidated Financial Statements Years Ended December 31, 2019 and 2018**

31, 2019 and 2018, the Company had no accounts deemed to be uncollectible and no reserve balances.

#### **Sales taxes**

Various states impose a sales tax on the Company's sales to non-exempt customers. The Company collects the sales tax from customers and remits the entire amount to each respective state. The Company's accounting policy is to exclude the tax collected and remitted to the states from revenue and cost of sales.

#### **Shipping and handling costs**

Shipping and handling costs are recorded as cost of revenue and amounts billed to customers for shipping and handling costs are netted against the shipping and handling costs.

#### **Property and equipment**

Property and equipment are recorded at cost. Expenditures for renewals and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized. Expenditures for maintenance and repairs are expensed as incurred. When equipment is retired or sold, the cost and related accumulated depreciation are eliminated from the balance sheet accounts and the resulting gain or loss is reflected in income.

Depreciation is calculated using the straight-line method, based on useful lives of the assets which range from three to five years.

The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property and equipment is used, and the effects of obsolescence, demand, competition, and other economic factors.

#### **Income taxes**

The Company has elected to be treated as a pass-through entity for income tax purposes and, as such, is not subject to income taxes. Rather, all items of taxable income, deductions and tax credits are passed through to and are reported by its owners on their respective income tax returns. The Company's federal tax status as a pass-through entity is based on its legal status as a limited liability company. Accordingly, the Company is not required to take any tax positions in order to qualify as a pass-through entity. The Company is required to file and does file tax returns with the Internal Revenue Services ("IRS") and other taxing authorities. Accordingly, these financial statements do not reflect a provision for income taxes and the Company has no other tax positions which must be considered for disclosure. Income tax returns filed by the Company are subject to examination by the IRS for a period of three



## **Pistil & Pollen, LLC and Subsidiaries**

### **Notes to Consolidated Financial Statements Years Ended December 31, 2019 and 2018**

years. While no income tax returns are currently being examined by the IRS, tax years since 2016 remain open. For income tax purposes, the Company reports on a calendar year basis.

#### **Revenue recognition**

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services has been rendered, the fee for the arrangement is fixed or determinable and collectability is reasonably assured.

#### **Advertising**

The Company expenses advertising costs as they are incurred. As of December 31, 2019 and 2018, advertising costs were \$19,944 and \$31,419, respectively.

#### **Recent accounting pronouncements**

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, *Revenue from Contracts with Customers*. Under this guidance, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that the Company receives or expects to receive for those goods or services. The updated standard will replace most existing revenue recognition guidance under U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. Early adoption is not permitted. The updated standard for nonpublic entities effective for annual periods beginning after December 15, 2018, and interim periods within annual reporting periods beginning after December 15, 2019. We are currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In February 2016, FASB issued ASU No. 2016-02, *Leases*, that requires organizations that lease assets, referred to as "lessees", to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard for nonpublic entities will be effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020, and early application is permitted. We are currently evaluating the effect that the updated standard will have on the consolidated financial statements and related disclosures.

In June 2020, FASB issued ASU No. 2020-05 ("ASU 2020-05"), *Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities*, which provides for the elective deferrals of the Topic 606 and Topic 842 for certain entities.

We have elected to apply the deferral provided by ASU 2020-05 and therefore expect to adopt Topic 606 during the year ending December 31, 2020 and Topic 842 during the year ending December 31, 2022.

The FASB issues ASUs to amend the authoritative literature in the Accounting Standards of Codification ("ASC"). There have been a number of ASUs to date, including those above, that amend the original text of the ASC. Management believes that those issued to date either (i)

**Pistil & Pollen, LLC and Subsidiaries**

**Notes to Consolidated Financial Statements  
Years Ended December 31, 2019 and 2018**

provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our consolidated financial statements.

**Subsequent events**

The Company has evaluated subsequent events through March 1, 2021, the date the consolidated financial statements were available to be issued, and concluded that subsequent events have occurred that require disclosure in the notes to the consolidated financial statements (see Note 8).

**Pistil & Pollen, LLC and Subsidiaries**

**Notes to Consolidated Financial Statements**  
**Years Ended December 31, 2019 and 2018**

**Note 3 - Restatement 2018 consolidated financial statements**

Management identified errors in accounts receivable, inventory, accounts payable, deferred wages, revenue, cost of revenues, general and administrative expenses, other income, and additional paid-in capital. The correction of those errors resulted in an increase in accounts receivable, increase in deferred wages, decrease in general and administrative expenses, decrease in net loss and increase in members' capital as of, and for the year ended, December 31, 2018.

The effects of the changes are as follows:

|                             |    | <u>Assets</u>            |               |                 |
|-----------------------------|----|--------------------------|---------------|-----------------|
|                             |    | December 31, 2018        |               |                 |
|                             |    | <u>Previously stated</u> | <u>Change</u> | <u>Restated</u> |
| Current assets              |    |                          |               |                 |
| Cash and cash equivalents   | \$ | 45,380                   | \$ -          | \$ 45,380       |
| Accounts receivable         |    | 451                      | 59,521        | 59,972          |
| Inventory                   |    | 56,578                   | 34,809        | 91,387          |
| Total current assets        |    | 102,409                  | 94,330        | 196,739         |
| Property and equipment, net |    | 26,431                   | -             | 26,431          |
| Other assets                |    |                          |               |                 |
| Trademarks                  |    | 79,132                   | -             | 79,132          |
| Total assets                | \$ | 207,972                  | \$ 94,330     | \$ 302,302      |

**Pistil & Pollen, LLC and Subsidiaries**

**Notes to Consolidated Financial Statements**  
**Years Ended December 31, 2019 and 2018**

Liabilities and Members' Capital (Deficit)

|  | December 31, 2018        |               |                 |
|--|--------------------------|---------------|-----------------|
|  | <u>Previously stated</u> | <u>Change</u> | <u>Restated</u> |
| Current liabilities                                  |                          |               |                 |
| Accounts payable                                     | \$ 127,616               | \$ 2,931      | \$ 130,547      |
| Deferred salaries                                    | 105,530                  | 16,946        | 122,476         |
| Total current liabilities                            | 233,146                  | 19,877        | 253,023         |
| Total liabilities                                    | 233,146                  | 19,877        | 253,023         |
| Members' capital (deficit)                           |                          |               |                 |
| Members' capital, contributions net of distributions | \$ 1,160,898             | \$ 125,000    | \$ 1,285,898    |
| Additional paid-in capital                           | 183,286                  | (22,531)      | 160,755         |
| Accumulated deficit                                  | (1,369,358)              | (28,016)      | (1,397,374)     |
| Total members' capital (deficit)                     | (25,174)                 | 74,453        | 49,279          |
| Total liabilities and members' capital (deficit)     | \$ 207,972               | \$ 94,330     | \$ 302,302      |

## Pistil & Pollen, LLC and Subsidiaries

### Notes to Consolidated Financial Statements Years Ended December 31, 2019 and 2018

|  | Year Ended December 31, 2018 |                    |                     |
|--|------------------------------|--------------------|---------------------|
| Revenues                                 | \$ 207,259                   | \$ (2,820)         | \$ 204,439          |
| Cost of revenues                         | <u>138,023</u>               | <u>(40,481)</u>    | <u>97,542</u>       |
| Gross profit                             | 69,236                       | 37,661             | 106,897             |
| Operating expenses                       |                              |                    |                     |
| General and administrative               | 460,748                      | (42,426)           | 418,322             |
| Sales and marketing                      | 59,123                       | (16,899)           | 42,224              |
| Depreciation expense                     | <u>14,417</u>                | <u>-</u>           | <u>14,417</u>       |
| Total operating expenses                 | <u>534,288</u>               | <u>(59,325)</u>    | <u>474,963</u>      |
| Net operating loss                       | <u>(465,052)</u>             | <u>96,986</u>      | <u>(368,066)</u>    |
| Other expenses                           |                              |                    |                     |
| Interest income                          | <u>2</u>                     | <u>(2)</u>         | <u>-</u>            |
| Total other expenses                     | <u>2</u>                     | <u>(2)</u>         | <u>-</u>            |
| Net loss                                 | <u>\$ (465,050)</u>          | <u>\$ 96,984</u>   | <u>\$ (368,066)</u> |
| Net cash flows from operating activities | <u>\$ (330,570)</u>          | <u>\$ 22,531</u>   | <u>\$ (308,039)</u> |
| Net cash flows from investing activities | <u>\$ (40,630)</u>           | <u>\$ -</u>        | <u>\$ (40,630)</u>  |
| Net cash flows from financing activities | <u>\$ 363,287</u>            | <u>\$ (22,531)</u> | <u>\$ 340,756</u>   |

#### Note 4 - Property and equipment

Property and equipment consist of tooling. The Company capitalizes property and equipment at cost, and depreciates each at a useful life of three years. As of December 31, 2019, and 2018, the Company had accumulated depreciation of \$31,236 and \$16,819, respectively.

#### Note 5 - Deferred salaries

The Chief Executive Officer, who is also a Member of the Company, has elected to defer the payment of her salary to a future period. As of December 31, 2019 and 2018, deferred wages were \$247,476 and \$122,476, respectively.

#### Note 6 - Members' capital

The Company has the following classes of ownership:

During 2016, 750,000 of Class A-1 units were issued to the original founder and certain strategic partners that helped with the formation of the Company. As of December 31, 2019 and 2018, 750,000 Class A-1 units were issued and outstanding, respectively. The Class A-1 Units were issued during 2016.

## **Pistil & Pollen, LLC and Subsidiaries**

### **Notes to Consolidated Financial Statements Years Ended December 31, 2019 and 2018**

During 2016, 750,000 units were issued to two investors. As of December 31, 2019 and 2018, all 750,000 remain outstanding.

Class A-1 and Class A-2 members each have the right to select a member of the three-person Board of Managers. The Class A-1 and Class A-2 members will receive a pro-rata return of capital with the Class B members and have rights to receive a 5 percent per annum return on their investment amounts. Additionally, the Class A-1 and Class A-2 units have non-dilution protection until the Company has raised at least \$2,000,000 in total capital from the sale of Class B units or through crowdfunding or other capital raising efforts.

Class B units represent the sale of 1,097,108 units to multiple investors from inception through 2019. The Company has authorized the issuance of \$1,200,000 of Class B units. The Class B units have a board seat controlled by the majority holder and the right to a return of capital pari passu with the Class A-1 and Class A-2 units. Class B units will then receive a share of profits after the Class A-1 and Class A-2.

Class C Units represent the issuance of 3,299,995 membership units to the original founders, advisors and key employees during 2016. These units are profit interests to be shared only after the Class A-1, Class A-2 and Class B Units have had their initial capital repaid and subsequent to the Class A-1 and Class A-2 units receiving their 5 percent per annum return. Class C Units do not have voting rights.

As of December 31, 2019 and 2018, the cumulative Class A-1 and A-2 Annual Priority Return is \$47,432 and \$34,932, respectively, and all of which remains unpaid to the Class A members.

#### **Simple Agreements for Future Equity ("SAFEs")**

In 2018, the Company has issued a total of \$187,017 in Simple Agreements for Future Equity ("SAFEs"). The Company incurred \$26,262 of costs related to the SAFE offering. Upon a future equity financing (an "Equity Financing") equal to or more than \$2,000,000, the SAFEs are convertible, at the option of the Company, into CF Shadow Series Securities, which are securities identical to those issued in the Equity Financing other than with respect to: (i) they do not have the right to vote on any matters except those required by law, (ii) they must vote in accordance with the majority of investors with respect to those required votes, and (iii) they are not entitled to any inspection or information rights. The Company does not have an obligation to convert the SAFEs.

Upon conversion, the Company will issue to the investor a number of shares of CF Shadow Series Securities. The number issued shall equal the quotient obtained by dividing the amount paid by the investors by the either the SAFE price (valuation cap of \$10,000,000 divided by the fully diluted capitalization of the Company) or the lowest price per share of the securities sold in the Equity Financing, whichever generates the highest number of equities ("Conversion Price").

## **Pistil & Pollen, LLC and Subsidiaries**

### **Notes to Consolidated Financial Statements Years Ended December 31, 2019 and 2018**

#### **Note 7 - Contingencies**

From time to time the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2019 and 2018, there is no known pending or threatened litigation against the Company.

#### **Note 8 - Subsequent events**

The Company has raised \$329,183 through crowdfunding from December 31, 2019 through the report date. The Company incurred \$39,938 of costs related to the SAFE offering.

The Crowdfunded Offering was made through OpenDeal Portal LLC (the "Intermediary", "Republic" or "Republic.co"). The Intermediary received a 6% commission fee and 2% of the securities issued in this offering.

During March 2020, an immediate family member of the Chief Executive Officer loaned the Company \$25,000. The loan was repaid on April 29, 2020.

On December 4, 2020, the Company executed a third amended and restated limited liability company agreement. This amended and restated operating agreement increased the amount of Class B units issued to 1,106,144 and the amount of Class C units to 3,299,996.

In the first quarter of 2020, an outbreak of a novel strain of a coronavirus ("COVID-19") emerged globally. As a result, federal, state and local authorities have implemented certain public safety mandates leading to an overall decline in economic activity which could result in a loss of revenue and other material adverse effects to the Company's financial position, results of operations, and cash flows. The Company is not able to estimate the length or severity of this outbreak and the related financial impact.